Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates

A US biotech company has announced a further $187.5 million in cash and cash equivalents for the first half of 2023, according to the latest figures from the US Department of Pharmaceuticals and Healthcare (DHS) in the Lancet.

Source: wallstreet-online.de
Published on 2023-05-01